The Chemours Company (NYSE:CC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• The Chemours Company has received a consensus rating of "Moderate Buy" from analysts, with five out of nine analysts recommending a buy.
• Recent analyst upgrades include price target increases from Mizuho and Truist Financial, raising their projections to as high as $21.00.
• CEO Denise Dignam purchased 4,068 shares of Chemours stock at approximately $12.06 per share, indicating insider confidence in the company's future.

Shares of The Chemours Company (NYSE:CC - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $17.6250.

A number of research analysts recently commented on the company. Mizuho upped their price objective on Chemours from $16.00 to $19.00 and gave the company an "outperform" rating in a report on Tuesday, September 23rd. Zacks Research raised Chemours from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Royal Bank Of Canada raised their price objective on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. Finally, Truist Financial boosted their price objective on shares of Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, September 16th.

Insider Buying and Selling at Chemours

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the firm's stock in a transaction on Friday, August 8th. The stock was bought at an average price of $12.06 per share, with a total value of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This represents a 2.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in shares of Chemours during the first quarter worth about $822,000. Principal Financial Group Inc. raised its holdings in Chemours by 116.3% in the first quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock valued at $10,041,000 after acquiring an additional 399,097 shares in the last quarter. Millennium Management LLC lifted its stake in Chemours by 60.4% in the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock worth $54,428,000 after acquiring an additional 1,515,520 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Chemours by 22.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 31,886 shares of the specialty chemicals company's stock worth $431,000 after acquiring an additional 5,843 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Chemours by 1,115.2% during the 1st quarter. GAMMA Investing LLC now owns 18,617 shares of the specialty chemicals company's stock worth $252,000 after acquiring an additional 17,085 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Price Performance

CC stock opened at $15.56 on Tuesday. Chemours has a 1 year low of $9.13 and a 1 year high of $22.38. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The firm has a market capitalization of $2.33 billion, a PE ratio of -5.56 and a beta of 1.61. The business has a 50 day simple moving average of $14.83 and a 200-day simple moving average of $12.94.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the firm earned $0.38 earnings per share. Chemours's quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Chemours will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 15th were given a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 15th. Chemours's payout ratio is currently -12.50%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.